Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent
Shots:
- Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain
- The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies
- Cerveau’s MK-6240 is a positron emission tomography (PET) used to scans neurofibrillary tangles (NFTs) in the brain. Cerveau Technologies also collaborated with Enigma Biomedical & Sinotau Pharmaceutical for its imaging agent
Ref: BusinessWire | Image: Bizjournals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com